Britain’s Clinigen Group Plc has agreed to a sweetened takeover offer by UK-based private equity firm Triton, valuing the pharmaceutical services firm at about $1.78bn.
Shareholders in Clinigen, whose top investor is hedge fund Elliott, will receive 925 pence per share in cash, up from a December bid of 883 pence apiece.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
New York-based Elliott, which had been raising its holding in Clinigen over the past few months amid reports it was seeking a break-up of the group, owns a 10.5% stake in the British company, according to Refintiv Eikon data.
The latest offer by Triley Bidco, a newly created company indirectly owned by Triton Funds, is final and is recommended by the Clinigen board, the companies said in a joint statement.
Triton’s first offer made in December valued Clinigen, which provides healthcare professionals and their patients with access to medicines, at about 1.2 billion pounds.
Source: FX Empire
Can’t stop reading? Read more
KKR and Blackstone anchor $100bn shift as India becomes Asia’s buyout hub
KKR and Blackstone anchor $100bn shift as India becomes Asia’s buyout hub KKR and Blackstone are...
Italian private equity firm Riello Investimenti takes 60% stake in iconic boatyard Apreamare
Italian private equity firm Riello Investimenti takes 60% stake in iconic boatyard Apreamare...
Samsung Life joins Mubadala and AXA IM Prime in backing $40bn lender Hayfin
Samsung Life joins Mubadala and AXA IM Prime in backing $40bn lender Hayfin Samsung Life Insurance...